Christopher Schroeder
Overview
Explore the profile of Christopher Schroeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
922
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schroeder C, Faust U, Krausse L, Liebmann A, Abele M, Demidov G, et al.
Eur J Hum Genet
. 2023 Jul;
31(10):1139-1146.
PMID: 37507557
The prevalence of pathogenic and likely pathogenic (P/LP) variants in genes associated with cancer predisposition syndromes (CPS) is estimated to be 8-18% for paediatric cancer patients. In more than half...
12.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, et al.
J Am Acad Dermatol
. 2023 Jul;
89(5):1072-1074.
PMID: 37487833
No abstract available.
13.
Reiter S, Schroeder C, Broche J, Sinnberg T, Bonzheim I, Susskind D, et al.
Front Oncol
. 2023 May;
13:1167791.
PMID: 37207136
Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors...
14.
Sachsenweger J, Jansche R, Merk T, Heitmeir B, Deniz M, Faust U, et al.
Cell Death Dis
. 2023 May;
14(5):328.
PMID: 37198153
It has been well-established that mutations in BRCA1 and BRCA2, compromising functions in DNA double-strand break repair (DSBR), confer hereditary breast and ovarian cancer risk. Importantly, mutations in these genes...
15.
Mittelstadt S, Kelemen O, Admard J, Gschwind A, Koch A, Worz S, et al.
Br J Cancer
. 2023 Mar;
128(11):2097-2103.
PMID: 36973448
Background: HPV-related cervical cancer (CC) is the fourth most frequent cancer in women worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response, residual disease, and relapse. We...
16.
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, et al.
Neurooncol Adv
. 2023 Mar;
5(1):vdad012.
PMID: 36915613
Background: The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular...
17.
Witt D, Faust U, Strobl-Wildemann G, Sturm M, Buchert R, Zuleger T, et al.
Mol Genet Genomic Med
. 2023 Feb;
11(6):e2151.
PMID: 36760167
Background: Lynch syndrome is one of the most common cancer predisposition syndromes. It is caused by inherited changes in the mismatch repair pathway. With current diagnostic approaches, a causative genetic...
18.
Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, et al.
Eur J Cancer
. 2022 Dec;
179:48-55.
PMID: 36495689
Background: Sequencing of tumour tissue with comprehensive gene panels is increasingly used to guide treatment in precision oncology. Analysis of tumour-normal pairs allows in contrast to tumour-only assessment direct discrimination...
19.
Guerrini-Rousseau L, Masliah-Planchon J, Waszak S, Alhopuro P, Benusiglio P, Bourdeaut F, et al.
J Med Genet
. 2022 Jun;
PMID: 35768194
Background: Little is known about risks associated with germline pathogenic variants (PVs) known as a cancer predisposition syndrome. Methods: To study tumour risks, we have analysed data of a large...
20.
Borde J, Laitman Y, Blumcke B, Niederacher D, Weber-Lassalle K, Sutter C, et al.
BMC Cancer
. 2022 Jun;
22(1):706.
PMID: 35761208
Background: Clinical management of women carrying a germline pathogenic variant (PV) in the BRCA1/2 genes demands for accurate age-dependent estimators of breast cancer (BC) risks, which were found to be...